AMAALA
11.3.2020 13:34:07 CET | Business Wire | Press release
AMAALA, the ultra-luxury destination located along Saudi Arabia’s northwestern coastline, has announced the appointment of leading architectural firm Denniston as the Master Planners for The Island.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200311005396/en/
Chief Executive Officer of AMAALA, Nicholas Naples, said : “AMAALA carves a unique positioning within the global hospitality portfolio, catering to select travellers looking for innovative experiential escapes. Our ambition is to create personalised experiences, catering to the individual needs of each guest. Entrenched in the philosophies of art, wellness, and inspired by the purity of the Red Sea, we are excited to be working alongside Jean-Michel Gathy and Denniston to bring to life our vision for The Island. It is here where our guests will embark on a transformational journey and feed the soul through arts and cultural offerings, with opportunities for philanthropic art co-creation.”
Representing one of AMAALA’s trio of communities, The Island will be the tranquil home of an exclusive art community, and an Arabic botanical garden bestrewn with sculptural pieces. The Island will house masterpieces across four key design elements: a contemporary art museum and academy, a Riviera-lifestyle artists’ colony, immersive artistic experiences, and art and sculpture co-creation opportunities.
Principal Designer of Denniston, Jean-Michel Gathy , said: “The Island development will be an immersive and interactive art-inspired jewel. Its lifestyle components, its landscaping, the museums, and art installations together with the art community will transform this island into the 'Diamond of the Red Sea'.
"It will feature many different venues for permanent installations or temporary exhibitions and artistic performances. The graphic layout of its spine will be distinctive from the air and will be recognised internationally as an iconic landmark. The project features all elements programmed and reflects the areas, numbers and facilities. This is truly unique, nothing like it has ever been planned before.”
The active community of The Island will be anchored by an artists' village of working studios, artisanal shops, galleries, plus exhibition and performance facilities hosting a year-round calendar of immersive, and transformative works, representing the pillar of arts and culture.
Fully aligned with Saudi Arabia’s ambitions for the future, the development of AMAALA is being rolled out across three key phases, with completion of the destination aimed for ahead of the realisation of Saudi Vision 2030.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200311005396/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors9.9.2026 15:45:00 CEST | Press release
- Recognized for the invention of a bispecific antibody that transformed treatment paradigm through an unconventional approach – Recognized for realizing a novel drug discovery concept in which a bispecific antibody replaces the function of coagulation Factor VIII, which is deficient in hemophilia A. Provided improved convenience through prolonged activity and subcutaneous administration, and provided a treatment option regardless of factor VIII inhibitors, thereby helping address unmet medical needs in hemophilia A. First time since the establishment of the Lasker Foundation in 1945 that three Japanese researchers have received the award simultaneously. Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that Dr. Kunihiro Hattori (former Senior Fellow of Chugai), Dr. Takehisa Kitazawa (Deputy Head of Research Division, Chugai), and Dr. Tomoyuki Igawa (Head of Research Division, Chugai), who led the creation of Hemlibra (emicizumab), a treatment for hemophilia A, have been aw
AMCS Appoints Richard Humphrey as Chief Product and Technology Officer9.9.2026 15:00:00 CEST | Press release
Industrial software executive to lead global product strategy and accelerate AI innovation AMCS, a leading technology provider for the waste and recycling industry, today announced the appointment of Richard Humphrey as Chief Product and Technology Officer. Based in Boston, Humphrey will lead the company’s global product organisation. Humphrey brings more than 25 years of experience developing software for construction and other complex industrial environments. He joins AMCS as the company deepens its focus on waste and recycling and expands the role of AI across its platform. Most recently, Humphrey served as Chief Product and Technology Officer at Contruent, where he led product strategy for a construction cost-management platform used on major capital programmes. He previously held vice president roles at Bentley Systems and B2W Software. Earlier in his career, he spent more than a decade at Autodesk, where he led its Civil Design and Construction software business as Senior Directo
BBH Launches a New Technology Business, Braid, Solving for Intelligent Data Transformation9.9.2026 14:45:00 CEST | Press release
Braid’s agentic AI platform is purpose-built for financial services firms who need to transform, connect, and manage their data with confidence Brown Brothers Harriman (BBH) today announced the launch of a new technology affiliate, Braid LLC, focused on solving enterprise data transformation for financial services. Braid offers an AI-native data transformation platform that gives firms a scale solution to transform, connect, and manage their data with confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909294398/en/ Braid empowers teams to build, automate, and oversee reliable production-grade data transformations in a fraction of the time typically required today. Instead of requiring engineers to build data automations, Braid allows business users to describe their needs in natural language that AI agents use to build intelligent data transformations that are transparent and fully auditable. Braid’s enterprise-gr
LTM Collaborates with IBM and Red Hat on Lightwell to Advance AI-Driven Open-Source Software Remediation9.9.2026 14:30:00 CEST | Press release
Strengthens software supply chains by helping enterprises transform vulnerability discovery into scalable remediation outcomes LTM, the Business Creativity partner to the world's largest enterprises, today announced that it has collaborated with IBM and Red Hat on Lightwell to help enterprises safeguard the open-source software supply chain through AI-driven vulnerability remediation. As AI accelerates the discovery of software vulnerabilities, organizations must move beyond detection-focused approaches and adopt enterprise-scale remediation strategies that enable rapid risk mitigation without disrupting business-critical applications. Lightwell’s approach of delivering validated fixes for production environments aligns with LTM's aim of helping customers build secure, resilient, and operationally efficient software supply chains. By combining AI-powered remediation capabilities with enterprise-grade validation and deployment support, Lightwell aims to help organizations address securi
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life9.9.2026 14:24:00 CEST | Press release
Data Demonstrated Significant and Clinically Meaningful Improvements with the Potential to Redefine Narcolepsy Type 1 (NT1) Care Beyond Individual Symptoms Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies Oveporexton is the First and Only Approved Orexin Agonist Designed to Treat the Underlying Cause of NT1 and is Now Approved in the U.S., China and Japan, with Additional Regulatory Submissions Underway Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).1 Oveporexton is the first and only medicine to treat the underlying cause of NT1. "People living with narcolepsy type 1 face persistent symptoms across the day and night, which can impact many aspects of daily life,” said Emmanuel Mignot, M.D., Ph.D., principal investigator for the FirstLight (TAK-86
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom